The Journal of Clinical Pharmacology · 2013 · 31 citations · 21 references
MedicineInfectious DiseasesPharmacologyPharmacogeneticsPharmacogenomicsVirologyAntiretroviral TherapyAntiviral PharmacologyAntiviral TherapyHiv EpidemiologyViral GeneticsFirst-line Antiretroviral RegimensHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyLogistic RegressionLogistic Regression AnalysisPharmacogenomics Of Antiretroviral TherapyProtease InhibitorsSingle-nucleotide Polymorphisms
The present study aims at evaluating the association between seven single nucleotide polymorphisms (SNPs) in five genes involved on antiretroviral pharmacokinetic pathways and virological failure in first line highly active antiretroviral therapy. Seven candidate polymorphisms (rs3842 and rs1045642 in ABCB1, rs212091 and rs3743527 in ABCC1, rs3745274 in CYP2B6, rs628031 in SLC22A1 and rs1517618 in SLCO3A1) were evaluated if they were associated with virological failure through logistic regression analysis. The study design was a retrospective cohort, analyzing 187 patients from Recife metropolitan region (Pernambuco, Brazil): among these 160 obtained complete suppression of HIV-1 replication (responders) and were compared to 27 non-responders, which underwent virological failure. There was no association between CYP2B6, SLC22A1, and SLCO3A1 SNPs and virological failure. Using logistic regression analysis, a significant association was detected between rs1045642 (3435C>T, ABCB1) and rs212091 (198217T>C; 3'-UTR, ABCC1) with virological failure of first-line antiretroviral regimens containing protease inhibitors, when controlled by clinical factors, such as sex, age and race. The present results could contribute to unravel the influence of genetic background in anti-HIV-1 therapy outcome and help in treatment personalization of Northeast Brazil HIV infected patients.
21
A Simple Sequentially Rejective Multiple Test Procedure
Sture Holm · Scandinavian Journal of Statistics · 1979 · 21.8K citations
The International HapMap Project
Richard A. Gibbs, John W. Belmont, Paul Hardenbol et al. · Nature · 2003 · 6.2K citations · Full text
Jacques Fellay, Catia Marzolini, E. Rhiannon Meaden et al. · The Lancet · 2002 · 662 citations · Full text
Bryan A. Ward, J. Christopher Gorski, David R. Jones et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 594 citations
Monika Hitzl, Siegfried Drescher, Heiko van der Kuip et al. · Pharmacogenetics · 2001 · 374 citations